Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Axcella Health Inc.AXLA · Entity 116059 | Director | May 20, 2021 | May 24, 2021 |
| Moderna, Inc.MRNA · Entity 2025 | President | September 14, 2026 | September 16, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Axcella Health Inc.
Report date May 20, 2021 · Filed May 24, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.24 · Expires 2031-05-19 | Direct | 20,000 |
Reported balance
After 2021-05-20 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-05-20 · Grant · Acquired 20,000 · Balance 20,000 F1: This option shall vest and become fully exercisable on the earlier of the first anniversary following the date of grant or the next scheduled Annual Meeting. |
Filing footnotes · ownership attribution and instrument terms
F1: This option shall vest and become fully exercisable on the earlier of the first anniversary following the date of grant or the next scheduled Annual Meeting.
Moderna, Inc.
Report date September 14, 2026 · Filed September 16, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,562,029 |
Ending reported balance
After 2026-09-15 transaction · row 4
4 source rows · reconciled sequenceRow 1 · 2026-09-14 · Exercise / conversion · Acquired 76,453 · Balance 1,566,152 F1: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on June 15, 2026. Row 2 · 2026-09-14 · Sale · Disposed 40,294 · Balance 1,525,858 F1: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on June 15, 2026. F2: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $143.99 to $144.66. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Row 3 · 2026-09-15 · Exercise / conversion · Acquired 76,452 · Balance 1,602,310 F1: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on June 15, 2026. Row 4 · 2026-09-15 · Sale · Disposed 40,281 · Balance 1,562,029 F1: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on June 15, 2026. F3: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $145.97 to $146.27. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.21 · Expires 2027-02-23 | Direct | 382,262 |
Reported balance
After 2026-09-14 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-09-14 · Exercise / conversion · Disposed 76,453 · Balance 382,262 F1: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on June 15, 2026. F5: This option is fully vested and exercisable. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.21 · Expires 2027-02-23 | Direct | 305,810 |
Reported balance
After 2026-09-15 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2026-09-15 · Exercise / conversion · Disposed 76,452 · Balance 305,810 F1: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on June 15, 2026. F5: This option is fully vested and exercisable. |
| Common StockSEC Table I · non-derivative | IndirectBy Valhalla, LLC | 4,116 |
Reported balance
Holding disclosure · report date 2026-09-14 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 4,116 |
| Common StockSEC Table I · non-derivative | IndirectBy Trust | 151,933 |
Reported balance
Holding disclosure · report date 2026-09-14 · row 6
Holding and transaction disclosures are not merged.
1 source rowRow 6 · Balance 151,933 F4: These shares are owned directly by a trust for the benefit of Dr. Hoge's spouse and children, of which his spouse is a trustee. The reporting person disclaims Section 16 beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose. |
Filing footnotes · ownership attribution and instrument terms
F1: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on June 15, 2026.
F2: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $143.99 to $144.66. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F3: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $145.97 to $146.27. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F4: These shares are owned directly by a trust for the benefit of Dr. Hoge's spouse and children, of which his spouse is a trustee. The reporting person disclaims Section 16 beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose.
F5: This option is fully vested and exercisable.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 07, 2025 Filed Feb 10, 2025 21:28 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionRestricted Stock Units · Derivative | 523 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-25-003835 · form4.xml · derivative · entry 5 Hoge Stephen · CIK 0001760669 · President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 523 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F1 · kind: Restricted stock units convert into common stock on a one-for-one basis. F4 · derivative.exercise_date: 25% of the shares subject to this restricted stock unit award vested on February 9, 2022 with the remainder vesting in twelve (12) equal quarterly installments thereafter. This restricted stock unit award is fully vested as of February 7, 2025. F4 · derivative.expiration_date: 25% of the shares subject to this restricted stock unit award vested on February 9, 2022 with the remainder vesting in twelve (12) equal quarterly installments thereafter. This restricted stock unit award is fully vested as of February 7, 2025. Read SEC document |
| February 07, 2025 Filed Feb 10, 2025 21:28 UTC | Moderna, Inc. MRNA · Entity 2025 | Tax withholdingCommon Stock | 281 | $33.61 | $9,444.41 |
DisclosureSEC source: 0001127602-25-003835 · form4.xml · nonDerivative · entry 2 Hoge Stephen · CIK 0001760669 · President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,444,146 F2 · kind: Represents shares withheld at the election of the Reporting Person to satisfy tax withholding obligations in connection with the vest of restricted stock units. Read SEC document |
| February 07, 2025 Filed Feb 10, 2025 21:28 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionCommon Stock | 523 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-25-003835 · form4.xml · nonDerivative · entry 1 Hoge Stephen · CIK 0001760669 · President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,444,427 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Restricted stock units convert into common stock on a one-for-one basis. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| December 03, 2024 Filed Dec 4, 2024 22:08 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 314 | $43.30 | $13,595.29 |
DisclosureSEC source: 0001127602-24-028663 · form4.xml · nonDerivative · entry 2 Hoge Stephen · CIK 0001760669 · President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,443,904 F2 · kind: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. Read SEC document |
| December 02, 2024 Filed Dec 4, 2024 22:08 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionRestricted Stock Units · Derivative | 651 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-028663 · form4.xml · derivative · entry 5 Hoge Stephen · CIK 0001760669 · President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,259 Underlying: Common Stock · 651 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F1 · kind: Restricted stock units convert into common stock on a one-for-one basis. F4 · derivative.exercise_date: 25% of the shares subject to this restricted stock unit award vested on March 1, 2023 with the remainder vesting in twelve (12) equal quarterly installments thereafter. F4 · derivative.expiration_date: 25% of the shares subject to this restricted stock unit award vested on March 1, 2023 with the remainder vesting in twelve (12) equal quarterly installments thereafter. Read SEC document |
| December 02, 2024 Filed Dec 4, 2024 22:08 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionCommon Stock | 651 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-24-028663 · form4.xml · nonDerivative · entry 1 Hoge Stephen · CIK 0001760669 · President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,444,218 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Restricted stock units convert into common stock on a one-for-one basis. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| November 29, 2024 Filed Dec 2, 2024 21:15 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 291 | $42.79 | $12,451.63 |
DisclosureSEC source: 0001127602-24-028295 · form4.xml · nonDerivative · entry 2 Hoge Stephen · CIK 0001760669 · President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,443,567 F2 · kind: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. Read SEC document |
| November 27, 2024 Filed Dec 2, 2024 21:15 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionRestricted Stock Units · Derivative | 610 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-028295 · form4.xml · derivative · entry 5 Hoge Stephen · CIK 0001760669 · President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,495 Underlying: Common Stock · 610 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F1 · kind: Restricted stock units convert into common stock on a one-for-one basis. F4 · derivative.exercise_date: 25% of the shares subject to this restricted stock unit award vested on February 28, 2024 with the remainder vesting in twelve (12) equal quarterly installments thereafter. F4 · derivative.expiration_date: 25% of the shares subject to this restricted stock unit award vested on February 28, 2024 with the remainder vesting in twelve (12) equal quarterly installments thereafter. Read SEC document |
| November 27, 2024 Filed Dec 2, 2024 21:15 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionCommon Stock | 610 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-24-028295 · form4.xml · nonDerivative · entry 1 Hoge Stephen · CIK 0001760669 · President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,443,858 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Restricted stock units convert into common stock on a one-for-one basis. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| November 11, 2024 Filed Nov 12, 2024 21:14 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 277 | $46.10 | $12,771.00 |
DisclosureSEC source: 0001127602-24-026997 · form4.xml · nonDerivative · entry 2 Hoge Stephen · CIK 0001760669 · President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,443,248 F2 · kind: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. Read SEC document |
| November 08, 2024 Filed Nov 12, 2024 21:14 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionRestricted Stock Units · Derivative | 523 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-026997 · form4.xml · derivative · entry 5 Hoge Stephen · CIK 0001760669 · President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 523 Underlying: Common Stock · 523 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F1 · kind: Restricted stock units convert into common stock on a one-for-one basis. F4 · derivative.exercise_date: 25% of the shares subject to this restricted stock unit award vested on February 9, 2022 with the remainder vesting in twelve (12) equal quarterly installments thereafter. F4 · derivative.expiration_date: 25% of the shares subject to this restricted stock unit award vested on February 9, 2022 with the remainder vesting in twelve (12) equal quarterly installments thereafter. Read SEC document |
| November 08, 2024 Filed Nov 12, 2024 21:14 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionCommon Stock | 523 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-24-026997 · form4.xml · nonDerivative · entry 1 Hoge Stephen · CIK 0001760669 · President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,443,525 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Restricted stock units convert into common stock on a one-for-one basis. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| September 03, 2024 Filed Sep 4, 2024 20:26 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 318 | $76.99 | $24,482.50 |
DisclosureSEC source: 0001127602-24-023402 · form4.xml · nonDerivative · entry 2 Hoge Stephen · CIK 0001760669 · President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,443,002 F2 · kind: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. Read SEC document |
| August 30, 2024 Filed Sep 4, 2024 20:26 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionRestricted Stock Units · Derivative | 652 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-023402 · form4.xml · derivative · entry 5 Hoge Stephen · CIK 0001760669 · President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,910 Underlying: Common Stock · 652 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F1 · kind: Restricted stock units convert into common stock on a one-for-one basis. F4 · derivative.exercise_date: 25% of the shares subject to this restricted stock unit award vested on March 1, 2023 with the remainder vesting in twelve (12) equal quarterly installments thereafter. F4 · derivative.expiration_date: 25% of the shares subject to this restricted stock unit award vested on March 1, 2023 with the remainder vesting in twelve (12) equal quarterly installments thereafter. Read SEC document |
| August 30, 2024 Filed Sep 4, 2024 20:26 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionCommon Stock | 652 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-24-023402 · form4.xml · nonDerivative · entry 1 Hoge Stephen · CIK 0001760669 · President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,443,320 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Restricted stock units convert into common stock on a one-for-one basis. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| August 29, 2024 Filed Aug 30, 2024 20:32 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 300 | $78.03 | $23,407.80 |
DisclosureSEC source: 0001127602-24-023235 · form4.xml · nonDerivative · entry 2 Hoge Stephen · CIK 0001760669 · President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,442,668 F2 · kind: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. Read SEC document |
| August 28, 2024 Filed Aug 30, 2024 20:32 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionRestricted Stock Units · Derivative | 611 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-023235 · form4.xml · derivative · entry 5 Hoge Stephen · CIK 0001760669 · President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,105 Underlying: Common Stock · 611 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F1 · kind: Restricted stock units convert into common stock on a one-for-one basis. F4 · derivative.exercise_date: 25% of the shares subject to this restricted stock unit award vested on February 28, 2024 with the remainder vesting in twelve (12) equal quarterly installments thereafter. F4 · derivative.expiration_date: 25% of the shares subject to this restricted stock unit award vested on February 28, 2024 with the remainder vesting in twelve (12) equal quarterly installments thereafter. Read SEC document |
| August 28, 2024 Filed Aug 30, 2024 20:32 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionCommon Stock | 611 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-24-023235 · form4.xml · nonDerivative · entry 1 Hoge Stephen · CIK 0001760669 · President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,442,968 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Restricted stock units convert into common stock on a one-for-one basis. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| August 12, 2024 Filed Aug 13, 2024 20:33 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 254 | $84.10 | $21,362.59 |
DisclosureSEC source: 0001127602-24-022080 · form4.xml · nonDerivative · entry 2 Hoge Stephen · CIK 0001760669 · President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,442,357 F2 · kind: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. Read SEC document |
| August 09, 2024 Filed Aug 13, 2024 20:33 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionRestricted Stock Units · Derivative | 522 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-022080 · form4.xml · derivative · entry 5 Hoge Stephen · CIK 0001760669 · President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,046 Underlying: Common Stock · 522 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F1 · kind: Restricted stock units convert into common stock on a one-for-one basis. F4 · derivative.exercise_date: 25% of the shares subject to this restricted stock unit award vested on February 9, 2022 with the remainder vesting in twelve (12) equal quarterly installments thereafter. F4 · derivative.expiration_date: 25% of the shares subject to this restricted stock unit award vested on February 9, 2022 with the remainder vesting in twelve (12) equal quarterly installments thereafter. Read SEC document |
| August 09, 2024 Filed Aug 13, 2024 20:33 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionCommon Stock | 522 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-24-022080 · form4.xml · nonDerivative · entry 1 Hoge Stephen · CIK 0001760669 · President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,442,611 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Restricted stock units convert into common stock on a one-for-one basis. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| July 15, 2024 Filed Jul 16, 2024 20:08 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 15,000 | $121.12 | $1,816,800.00 |
DisclosureSEC source: 0001127602-24-020509 · form4.xml · nonDerivative · entry 1 Hoge Stephen · CIK 0001760669 · President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,442,089 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 15, 2023. Read SEC document |
| June 17, 2024 Filed Jun 18, 2024 20:05 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 15,000 | $138.16 | $2,072,400.00 |
DisclosureSEC source: 0001127602-24-018901 · form4.xml · nonDerivative · entry 1 Hoge Stephen · CIK 0001760669 · President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,457,089 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 15, 2023. Read SEC document |
| June 03, 2024 Filed Jun 4, 2024 21:20 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 339 | $140.72 | $47,704.01 |
DisclosureSEC source: 0001127602-24-017754 · form4.xml · nonDerivative · entry 2 Hoge Stephen · CIK 0001760669 · President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,472,089 F2 · kind: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. Read SEC document |
| May 31, 2024 Filed Jun 4, 2024 21:20 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionRestricted Stock Units · Derivative | 651 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-017754 · form4.xml · derivative · entry 5 Hoge Stephen · CIK 0001760669 · President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,562 Underlying: Common Stock · 651 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F1 · kind: Restricted stock units convert into common stock on a one-for-one basis. F4 · derivative.exercise_date: 25% of the shares subject to this restricted stock unit award vested on March 1, 2023 with the remainder vesting in twelve (12) equal quarterly installments thereafter. F4 · derivative.expiration_date: 25% of the shares subject to this restricted stock unit award vested on March 1, 2023 with the remainder vesting in twelve (12) equal quarterly installments thereafter. Read SEC document |
| May 31, 2024 Filed Jun 4, 2024 21:20 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionCommon Stock | 651 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-24-017754 · form4.xml · nonDerivative · entry 1 Hoge Stephen · CIK 0001760669 · President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,472,428 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Restricted stock units convert into common stock on a one-for-one basis. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| May 29, 2024 Filed May 30, 2024 20:14 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 341 | $144.50 | $49,276.10 |
DisclosureSEC source: 0001127602-24-016963 · form4.xml · nonDerivative · entry 2 Hoge Stephen · CIK 0001760669 · President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,471,777 F2 · kind: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. Read SEC document |
| May 28, 2024 Filed May 30, 2024 20:14 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionRestricted Stock Units · Derivative | 610 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-016963 · form4.xml · derivative · entry 5 Hoge Stephen · CIK 0001760669 · President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,716 Underlying: Common Stock · 610 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F1 · kind: Restricted stock units convert into common stock on a one-for-one basis. F4 · derivative.exercise_date: 25% of the shares subject to this restricted stock unit award vested on February 28, 2024 with the remainder vesting in twelve (12) equal quarterly installments thereafter. F4 · derivative.expiration_date: 25% of the shares subject to this restricted stock unit award vested on February 28, 2024 with the remainder vesting in twelve (12) equal quarterly installments thereafter. Read SEC document |
| May 28, 2024 Filed May 30, 2024 20:14 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionCommon Stock | 610 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-24-016963 · form4.xml · nonDerivative · entry 1 Hoge Stephen · CIK 0001760669 · President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,472,118 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Restricted stock units convert into common stock on a one-for-one basis. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| May 15, 2024 Filed May 17, 2024 20:04 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 15,000 | $127.49 | $1,912,350.00 |
DisclosureSEC source: 0001127602-24-015809 · form4.xml · nonDerivative · entry 1 Hoge Stephen · CIK 0001760669 · President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,471,508 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 15, 2023. Read SEC document |
| May 10, 2024 Filed May 13, 2024 20:03 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 255 | $120.96 | $30,844.11 |
DisclosureSEC source: 0001127602-24-015081 · form4.xml · nonDerivative · entry 2 Hoge Stephen · CIK 0001760669 · President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,486,508 F2 · kind: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. Read SEC document |
| May 09, 2024 Filed May 13, 2024 20:03 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionRestricted Stock Units · Derivative | 522 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-015081 · form4.xml · derivative · entry 5 Hoge Stephen · CIK 0001760669 · President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,568 Underlying: Common Stock · 522 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F1 · kind: Restricted stock units convert into common stock on a one-for-one basis. F4 · derivative.exercise_date: 25% of the shares subject to this restricted stock unit award vested on February 9, 2022 with the remainder vesting in twelve (12) equal quarterly installments thereafter. F4 · derivative.expiration_date: 25% of the shares subject to this restricted stock unit award vested on February 9, 2022 with the remainder vesting in twelve (12) equal quarterly installments thereafter. Read SEC document |
| May 09, 2024 Filed May 13, 2024 20:03 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionCommon Stock | 522 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-24-015081 · form4.xml · nonDerivative · entry 1 Hoge Stephen · CIK 0001760669 · President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,486,763 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Restricted stock units convert into common stock on a one-for-one basis. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| April 15, 2024 Filed Apr 16, 2024 20:23 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 15,000 | $105.02 | $1,575,300.00 |
DisclosureSEC source: 0001127602-24-012991 · form4.xml · nonDerivative · entry 1 Hoge Stephen · CIK 0001760669 · President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,486,241 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 15, 2023. Read SEC document |
| March 15, 2024 Filed Mar 19, 2024 20:39 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 15,000 | $103.17 | $1,547,550.00 |
DisclosureSEC source: 0001127602-24-010623 · form4.xml · nonDerivative · entry 1 Hoge Stephen · CIK 0001760669 · President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,501,241 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 15, 2023. Read SEC document |
| March 04, 2024 Filed Mar 5, 2024 22:52 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 309 | $94.34 | $29,150.53 |
DisclosureSEC source: 0001127602-24-008668 · form4.xml · nonDerivative · entry 4 Hoge Stephen · CIK 0001760669 · President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,516,241 F3 · kind: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. Read SEC document |
| March 01, 2024 Filed Mar 5, 2024 22:52 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionRestricted Stock Units · Derivative | 652 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-008668 · form4.xml · derivative · entry 5 Hoge Stephen · CIK 0001760669 · President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,213 Underlying: Common Stock · 652 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F2 · kind: Restricted stock units convert into common stock on a one-for-one basis. F4 · derivative.exercise_date: 25% of the shares subject to this restricted stock unit award vested on March 1, 2023 with the remainder vesting in twelve (12) equal quarterly installments thereafter. F4 · derivative.expiration_date: 25% of the shares subject to this restricted stock unit award vested on March 1, 2023 with the remainder vesting in twelve (12) equal quarterly installments thereafter. Read SEC document |
| March 01, 2024 Filed Mar 5, 2024 22:52 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionCommon Stock | 652 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-24-008668 · form4.xml · nonDerivative · entry 3 Hoge Stephen · CIK 0001760669 · President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,516,550 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: Restricted stock units convert into common stock on a one-for-one basis. F2 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| February 29, 2024 Filed Mar 1, 2024 22:25 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 2,388 | $94.57 | $225,837.94 |
DisclosureSEC source: 0001127602-24-007935 · form4.xml · nonDerivative · entry 5 Hoge Stephen · CIK 0001760669 · President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,515,898 F3 · kind: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. Read SEC document |
| February 28, 2024 Filed Mar 1, 2024 22:25 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionRestricted Stock Units · Derivative | 2,442 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-007935 · form4.xml · derivative · entry 7 Hoge Stephen · CIK 0001760669 · President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,326 Underlying: Common Stock · 2,442 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F2 · kind: Restricted stock units convert into common stock on a one-for-one basis. F5 · derivative.exercise_date: 25% of the shares subject to this restricted stock unit award vested on February 28, 2024 with the remainder vesting in twelve (12) equal quarterly installments thereafter. F5 · derivative.expiration_date: 25% of the shares subject to this restricted stock unit award vested on February 28, 2024 with the remainder vesting in twelve (12) equal quarterly installments thereafter. Read SEC document |
| February 28, 2024 Filed Mar 1, 2024 22:25 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionRestricted Stock Units · Derivative | 2,411 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-007935 · form4.xml · derivative · entry 6 Hoge Stephen · CIK 0001760669 · President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,411 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F2 · kind: Restricted stock units convert into common stock on a one-for-one basis. F4 · derivative.exercise_date: 50% of the shares subject to this restricted stock unit award vested on February 28, 2022 with the remainder vesting in eight (8) equal quarterly installments thereafter. F4 · derivative.expiration_date: 50% of the shares subject to this restricted stock unit award vested on February 28, 2022 with the remainder vesting in eight (8) equal quarterly installments thereafter. Read SEC document |
| February 28, 2024 Filed Mar 1, 2024 22:25 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionCommon Stock | 2,442 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-24-007935 · form4.xml · nonDerivative · entry 4 Hoge Stephen · CIK 0001760669 · President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,518,286 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: Restricted stock units convert into common stock on a one-for-one basis. F2 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| February 28, 2024 Filed Mar 1, 2024 22:25 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionCommon Stock | 2,411 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-24-007935 · form4.xml · nonDerivative · entry 3 Hoge Stephen · CIK 0001760669 · President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,515,844 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: Restricted stock units convert into common stock on a one-for-one basis. F2 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| February 27, 2024 Filed Feb 29, 2024 21:32 UTC | Moderna, Inc. MRNA · Entity 2025 | GrantRestricted Stock Units · Derivative | 22,987 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-007627 · form4.xml · derivative · entry 5 Hoge Stephen · CIK 0001760669 · President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,987 Underlying: Common Stock · 22,987 shares Expires not disclosed F3 · derivative.exercise_date: 25% of the shares subject to this restricted stock unit award will vest on February 27, 2025 with the remainder vesting in twelve (12) equal quarterly installments thereafter. F3 · derivative.expiration_date: 25% of the shares subject to this restricted stock unit award will vest on February 27, 2025 with the remainder vesting in twelve (12) equal quarterly installments thereafter. Read SEC document |
| February 27, 2024 Filed Feb 29, 2024 21:32 UTC | Moderna, Inc. MRNA · Entity 2025 | GrantStock Option (Right to Buy) · Derivative | 43,894 | $0.00 Strike: $96.20 | $0.00 |
DisclosureSEC source: 0001127602-24-007627 · form4.xml · derivative · entry 4 Hoge Stephen · CIK 0001760669 · President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 43,894 Underlying: Common Stock · 43,894 shares Expires 2034-02-27 F2 · derivative.exercise_date: 25% of this option will vest and become exercisable on February 27, 2025 with the remainder vesting in twelve (12) equal quarterly installments thereafter. Read SEC document |
| February 22, 2024 Filed Feb 23, 2024 21:04 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 15,000 | $100.00 | $1,500,000.00 |
DisclosureSEC source: 0001127602-24-006556 · form4.xml · nonDerivative · entry 1 Hoge Stephen · CIK 0001760669 · President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,513,433 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 15, 2023. Read SEC document |
| February 16, 2024 Filed Feb 16, 2024 21:19 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 10,542 | $88.88 | $936,981.39 |
DisclosureSEC source: 0001127602-24-005364 · form4.xml · nonDerivative · entry 4 Hoge Stephen · CIK 0001760669 · President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,528,433 F3 · kind: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the 2021 PSUs. This "sell-to-cover" transaction was mandated by the Issuer's equity incentive plan and does not represent a discretionary trade by the reporting person. Read SEC document |
| February 14, 2024 Filed Feb 16, 2024 21:19 UTC | Moderna, Inc. MRNA · Entity 2025 | GrantCommon Stock | 22,694 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-005364 · form4.xml · nonDerivative · entry 3 Hoge Stephen · CIK 0001760669 · President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,538,975 F2 · kind: The reported transaction is the vesting of performance-based restricted stock units granted to the reporting person on March 5, 2021 (the "2021 PSUs"). Read SEC document |
| February 12, 2024 Filed Feb 13, 2024 21:13 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 304 | $86.23 | $26,213.68 |
DisclosureSEC source: 0001127602-24-004682 · form4.xml · nonDerivative · entry 4 Hoge Stephen · CIK 0001760669 · President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,516,281 F3 · kind: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. Read SEC document |
| February 09, 2024 Filed Feb 13, 2024 21:13 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionRestricted Stock Units · Derivative | 522 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-004682 · form4.xml · derivative · entry 5 Hoge Stephen · CIK 0001760669 · President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,090 Underlying: Common Stock · 522 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F2 · kind: Restricted stock units convert into common stock on a one-for-one basis. F4 · derivative.exercise_date: 25% of the shares subject to this restricted stock unit award vested on February 9, 2022 with the remainder vesting in twelve (12) equal quarterly installments thereafter. F4 · derivative.expiration_date: 25% of the shares subject to this restricted stock unit award vested on February 9, 2022 with the remainder vesting in twelve (12) equal quarterly installments thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.